QuVa Pharma has added another forward distribution center to its existing 503B sterile injectable compounded medications platform. Quva now has two dedicated forward distribution facilities, with the new 20,000 sq. ft. distribution facility in Sugar Land, TX providing additional overall capacity beyond that offered by the company's existing 40,000 sq. ft. distribution facility in Phoenix, AZ.
Located in close proximity to Quva's Sugar Land, TX manufacturing operations, this new forward distribution center was designed to meet the growing demand for secure, efficient, and compliant product handling and shipping. It enhances the company's supply chain capabilities with cutting-edge infrastructure that supports cold chain and DEA regulatory compliance. This new facility represents a major investment in operational excellence and regulatory compliance and further increases capacity in Quva's production facilities. Furthermore, this distribution facility will be co-located with Quva's new, state-of-the-art IV bag production operations that will implement automated processes that improve bag operations from end-to-end manufacturing—this is scheduled to be operational in the second half of 2026 and increase Quva's overall production capacity to three facilities and over 260,000 sq.ft. across its network.
"Quva is building a new future of reliability and transparency for our industry. This newest distribution center is progress in our mission to provide high quality and effective medications and services to facilitate efficient and accurate delivery of patient care," said Stuart Hinchen, Quva co-founder and CEO. "We understand hospitals' need for the right drug at the right time and in the right quantities, and with uncertainties like tariffs and DSCSA implementation being front and center for our customers, this added capability to increase access and reliability is critical to help meet those expectations."